New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting TSHA-102, engineered with novel miRARE technology,
Pharvaris NV (NASDAQ: PHVS) announced that the FDA lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant (PHA-121) for the on-demand